The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies

Objectives: The kynurenine (KYN) pathway has been attracting attention as a relevant pathway in schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We conducted a systematic review and meta-analysis of studies examining KYN pathway metabolites from cerebrospinal fluid (C...

Full description

Bibliographic Details
Main Authors: Mehmet Enes Inam, Brisa S. Fernandes, Estela Salagre, Iria Grande, Eduard Vieta, João Quevedo, Zhongming Zhao
Format: Article
Language:English
Published: Associação Brasileira de Psiquiatria (ABP) 2023-08-01
Series:Brazilian Journal of Psychiatry
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462023005006201&lng=en&tlng=en
_version_ 1797733719576936448
author Mehmet Enes Inam
Brisa S. Fernandes
Estela Salagre
Iria Grande
Eduard Vieta
João Quevedo
Zhongming Zhao
author_facet Mehmet Enes Inam
Brisa S. Fernandes
Estela Salagre
Iria Grande
Eduard Vieta
João Quevedo
Zhongming Zhao
author_sort Mehmet Enes Inam
collection DOAJ
description Objectives: The kynurenine (KYN) pathway has been attracting attention as a relevant pathway in schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We conducted a systematic review and meta-analysis of studies examining KYN pathway metabolites from cerebrospinal fluid (CSF) samples in SZ, BD, and MDD. Methods: The PubMed and Scopus databases were systematically searched to identify peer-reviewed case-control studies published until April 2022 that assessed KYN metabolites, namely, tryptophan (TRP), KYN, kynurenic acid (KA), quinolinic acid (QA), and 3-hydroxykynurenine (3-HK), in subjects with SZ, BD, or MDD compared with healthy controls (HC). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The random effects model method was selected for comparison of standardized mean differences (SMD) between two groups. Results: Twenty-three articles met the inclusion criteria (k = 8, k = 8, k = 11, for SZ, BD, and MDD, respectively). In SZ, KA levels were increased (SMD = 2.64, confidence interval [CI] = 1.16 to 4.13, p = 0.0005, I2 = 96%, k = 6, n=384). TRP (k = 5) and KYN (k = 4) did not differ significantly. In BD, TRP levels (k = 7) did not differ significantly. The level of KA was increased in MDD (k = 2), but the small number of studies precluded evaluation of statistical significance. Finally, in MDD, although some studies tended to show an increased level of KYN in those with remission vs. decreased levels in those with current depression, no significant difference was found in any KYN metabolite levels. Similarly, an increased level of QA was found, but the number of studies (k = 2) was small. Conclusion: KA, which has possibly neuroprotective effects, is increased in SZ. QA, which has neurotoxic effects, may be increased in MDD. There were no alterations in BD. Alterations in the KYN pathway may occur based on population characteristics and mood states. Future studies should explore the utility of these metabolites as biomarkers.
first_indexed 2024-03-12T12:32:14Z
format Article
id doaj.art-d2406fc9d1b84dd2a01faa2e1d94423e
institution Directory Open Access Journal
issn 1809-452X
language English
last_indexed 2024-03-12T12:32:14Z
publishDate 2023-08-01
publisher Associação Brasileira de Psiquiatria (ABP)
record_format Article
series Brazilian Journal of Psychiatry
spelling doaj.art-d2406fc9d1b84dd2a01faa2e1d94423e2023-08-29T07:48:00ZengAssociação Brasileira de Psiquiatria (ABP)Brazilian Journal of Psychiatry1809-452X2023-08-0110.47626/1516-4446-2022-2973The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studiesMehmet Enes Inamhttps://orcid.org/0000-0002-6779-9377Brisa S. Fernandeshttps://orcid.org/0000-0002-3797-7582Estela SalagreIria Grandehttps://orcid.org/0000-0002-0137-0666Eduard Vietahttps://orcid.org/0000-0002-0548-0053João Quevedohttps://orcid.org/0000-0003-3114-6611Zhongming Zhaohttps://orcid.org/0000-0002-3477-0914 Objectives: The kynurenine (KYN) pathway has been attracting attention as a relevant pathway in schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We conducted a systematic review and meta-analysis of studies examining KYN pathway metabolites from cerebrospinal fluid (CSF) samples in SZ, BD, and MDD. Methods: The PubMed and Scopus databases were systematically searched to identify peer-reviewed case-control studies published until April 2022 that assessed KYN metabolites, namely, tryptophan (TRP), KYN, kynurenic acid (KA), quinolinic acid (QA), and 3-hydroxykynurenine (3-HK), in subjects with SZ, BD, or MDD compared with healthy controls (HC). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The random effects model method was selected for comparison of standardized mean differences (SMD) between two groups. Results: Twenty-three articles met the inclusion criteria (k = 8, k = 8, k = 11, for SZ, BD, and MDD, respectively). In SZ, KA levels were increased (SMD = 2.64, confidence interval [CI] = 1.16 to 4.13, p = 0.0005, I2 = 96%, k = 6, n=384). TRP (k = 5) and KYN (k = 4) did not differ significantly. In BD, TRP levels (k = 7) did not differ significantly. The level of KA was increased in MDD (k = 2), but the small number of studies precluded evaluation of statistical significance. Finally, in MDD, although some studies tended to show an increased level of KYN in those with remission vs. decreased levels in those with current depression, no significant difference was found in any KYN metabolite levels. Similarly, an increased level of QA was found, but the number of studies (k = 2) was small. Conclusion: KA, which has possibly neuroprotective effects, is increased in SZ. QA, which has neurotoxic effects, may be increased in MDD. There were no alterations in BD. Alterations in the KYN pathway may occur based on population characteristics and mood states. Future studies should explore the utility of these metabolites as biomarkers.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462023005006201&lng=en&tlng=enBiomarkerkynurenic acidquinolinic acidtryptophanmental disorders
spellingShingle Mehmet Enes Inam
Brisa S. Fernandes
Estela Salagre
Iria Grande
Eduard Vieta
João Quevedo
Zhongming Zhao
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
Brazilian Journal of Psychiatry
Biomarker
kynurenic acid
quinolinic acid
tryptophan
mental disorders
title The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
title_full The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
title_fullStr The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
title_full_unstemmed The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
title_short The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
title_sort kynurenine pathway in major depressive disorder bipolar disorder and schizophrenia a systematic review and meta analysis of cerebrospinal fluid studies
topic Biomarker
kynurenic acid
quinolinic acid
tryptophan
mental disorders
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462023005006201&lng=en&tlng=en
work_keys_str_mv AT mehmetenesinam thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT brisasfernandes thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT estelasalagre thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT iriagrande thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT eduardvieta thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT joaoquevedo thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT zhongmingzhao thekynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT mehmetenesinam kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT brisasfernandes kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT estelasalagre kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT iriagrande kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT eduardvieta kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT joaoquevedo kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies
AT zhongmingzhao kynureninepathwayinmajordepressivedisorderbipolardisorderandschizophreniaasystematicreviewandmetaanalysisofcerebrospinalfluidstudies